BIOTECH GILEAD MAY BECOME THE FUTURE LEADER IN SOLID TUMOR CANCER TREATMENT — A STOCK MARKET OPPORTUNITY $GILD $IMMU
This is the golden age of biotech. Huge profits are to be made by astute investors from biotech breakthroughs. One great opportunity for long term investors is Gilead (GILD). Gilead is one of the cheapest large cap biotechs around. Gilead just bought Immunomedics (IMMU). In our analysis, Gilead has the